China News Service, September 9 – The China-Kazakhstan Economic and Trade Forum recently took place at the China-Kazakhstan Khorgos International Border Cooperation Center. Concurrently with the forum, the China Anti-Aging Promotion Association, in collaboration with Jiuzhitang, officially launched the "Cardiovascular & Cerebrovascular Health and Anti-Aging Promotion Project." This initiative will leverage Jiuzhitang's nationwide network of Traditional Chinese Medicine clinics as its primary outreach hubs. Grounded in the philosophy of integrating traditional Chinese medicine, precision medicine, and smart healthcare, the project will offer a comprehensive range of services, including functional medicine, disease risk analysis and early warning, online consultations, digital pharmacy access, remote medical consultations, and personalized physician care. Designed to meet the evolving health management needs of people in the new era, the program aims to provide tailored, full-lifecycle health solutions.

During the forum, Li Zhenguo, President of Jiuzhitang Group and Chairman of Jiuzhitang Co., Ltd., along with Milan from Kazakhstan’s ALTACO Company, jointly unveiled the Jiuzhitang-ALTACO International Medical Center, witnessed by attendees of the event. This marks the official establishment of the center within the China-Kazakhstan Khorgos Border Cooperation Zone. This initiative reflects Jiuzhitang’s confident and inclusive approach—building on the unparalleled strengths of Traditional Chinese Medicine while seamlessly integrating Western medical practices, embracing the best of modern medicine to enhance patient care. By combining the innovative potential of both Eastern and Western healing methods, Jiuzhitang is delivering maximum benefits to patients. Moreover, this move underscores Jiuzhitang’s forward-thinking strategy to align with national healthcare and economic development goals, showcasing the successful integration of traditional and regenerative medicine—and fostering deeper medical, health, and economic cooperation between China and Kazakhstan. 　　

Traditional Chinese medicine is a treasure of human civilization, having nurtured the health of people in China for thousands of years. Regenerative medicine—driven by advancements in biotechnology and the clinical application of stem cells—is leading the future direction of medical innovation, addressing society's growing aspirations for longer, healthier lives and anti-aging solutions. By leveraging the strengths of both traditional and regenerative medicine, and exploring innovative integration models, Jiuzhitang is pioneering ways to preserve and enhance the role of traditional Chinese medicine within the Healthy Silk Road initiative. At the same time, the company is actively sharing cutting-edge clinical research findings on stem-cell therapies for severe neurological disorders and cardiac rehabilitation, aiming to deliver personalized, precision health services that span every stage of life.

As Li Zhenguo rightly pointed out, whether it’s traditional or modern medicine, their core value ultimately lies in serving human health. In the process of integrating and evolving traditional and modern medical approaches, it’s crucial to firmly embrace cultural confidence while steadfastly upholding the principles of both heritage preservation and innovative development. Nine Ginseng Hall has proactively positioned itself by strategically transforming the company and restructuring its product portfolio. Today, its two key areas—stem cell therapies and antibody drugs—are acting as powerful accelerators, propelling the century-old brand toward rapid growth and success.

Cao Hongxin, former president of the China Academy of Traditional Chinese Medicine, stated that Jiuzhitang's promotion of collaboration between traditional medicine and regenerative medicine represents a pioneering effort to integrate these two fields. This initiative lays the groundwork for showcasing China's unique approach to healthcare systems on the global stage, serving as a model for others to follow. By firmly upholding cultural confidence, preserving the distinctive features of TCM, unlocking its intrinsic value, and fostering innovative approaches to TCM development, we can better support the vision of a Healthy China.

It is reported that the "Jiuzhitang-ALTACO International Medical Center" was established through a partnership between Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. and Kazakhstan’s LLP “ALTACO-XXI” company. In 2018, Jiuzhitang recognized the unique advantages and growing trends of stem cell therapies in treating severe illnesses, immune disorders, and for overall health management. To capitalize on this opportunity, the company took an active role in launching and setting up a merger and acquisition fund, ultimately investing in the U.S.-based Stemedica Corporation. As a result, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. was founded as the exclusive recipient of Stemedica’s cutting-edge stem cell technology. Currently, construction is underway at a state-of-the-art facility in Beijing’s Daxing District, designed to meet China’s, the European Union’s, and the U.S.’s cGMP certification standards. In January 2019, Jiuzhitang Maker and LLP “ALTACO-XXI” signed a collaboration agreement within the Khorgos China-Kazakhstan Cooperation Zone to jointly implement clinical research projects. Notably, Stemedica’s stem cell therapy for acute myocardial infarction has already received approval from Kazakhstan’s Ministry of Health for commercialization. The center is dedicated to advancing innovative, cutting-edge scientific research, seamlessly integrating precision medicine with regenerative medicine in clinical applications. By doing so, it aims to provide specialized, safe, and reliable healthcare services tailored to patients suffering from life-threatening conditions—particularly those lacking effective treatment options—as well as individuals grappling with cardiovascular, neurological, and immune-related diseases. Additionally, the center caters to high-end clients seeking advanced anti-aging solutions. Ultimately, the center strives to meet and exceed both domestic and international demands for health and anti-aging care, while fostering the continued growth of the medical and anti-aging industries.

The Jiuzhitang-ALTACO Stem Cell International Medical Center is a key initiative by Jiuzhitang, driven by the company’s development philosophy that blends "inheritance with innovation." Dedicated to addressing the evolving health needs of humanity across different historical eras, the center is strategically positioned at the forefront of modern and regenerative medicine. Founded in 1650, Jiuzhitang has long been recognized as a national-level key enterprise specializing in traditional Chinese medicine, a national high-tech enterprise, a time-honored Chinese brand, and a national-level unit safeguarding intangible cultural heritage. For over 300 years, Jiuzhitang has steadfastly upheld the timeless principle: "A pharmacist must devote their utmost effort, while a physician should always act with integrity," continuously striving to protect and enhance the health of people across China.

Li Zhenguo openly admitted that Jiuzhitang remains committed to its original mission of inheriting and innovating, continuously exploring new ideas and strategies to drive the development of China’s traditional Chinese medicine industry. The establishment of the "Jiuzhitang International Medical Center" and the launch of the "Cardiovascular & Cerebral Health and Anti-Aging Promotion Project" will not only accelerate the international dissemination of TCM culture but also catalyze the rapid advancement of stem-cell technology—a cutting-edge medical innovation—while boosting the overall growth of China’s stem-cell-based pharmaceutical sector. In doing so, the century-old brand Jiuzhitang aims to play a pivotal role in enhancing the global competitiveness of China’s regenerative medicine field.